Foldamers: Novel Ligands for Diverse Protein Surfaces

Foldamers：用于多种蛋白质表面的新型配体

• 批准号: 6956144
• 负责人: Alanna Schepartz
• 金额: $ 43.85万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6956144
• 关键词: Coronaviridae; HIV envelope protein; drug design /synthesis /production; glycoproteins; hydropathy; ligands; method development; nuclear magnetic resonance spectroscopy; p53 gene /protein; peptide chemical synthesis; peptide library; protein binding; protein protein interaction; protein structure function; respiratory syncytial virus; severe acute respiratory syndrome; virus envelope; virus protein

DESCRIPTION (provided by applicant): This application builds on a foundation of recent results from our laboratory detailing a general strategy for the design of beta-peptides that are highly 14-helical in water and bind with high affinity to protein surfaces, such as the p53AD interaction domain of hDM2. In Aim 1 we explore the structural features that contribute to 14-helix stability in water and the ability of the 14-helical beta-peptide beta53-1 to recognize protein surfaces. We will complete an extensive "host-guest" analysis that will classify all proteinogenic and selected non-proteinogenic side chains as 14-helix stabilizing, destabilizing, or neutral, generating a database of position-dependent, 14-helix propensities in water; determine the NMR solution structure of beta53-1 to support the host-guest data and guide future design efforts; and explore whether the stability or affinity of beta53-1 can be improved by introduction of cyclic ACHC residues. In Aim 2 we build on the results of Aim 1 to design beta-peptide ligands for the envelope glycoproteins of 3 viruses that threaten human health, national security, or both: HIV, human respiratory syncytial virus (HRSV), and the coronavirus that causes severe acute respiratory syndrome (SARS-CoV). The experiments in Aim 2 will validate our betapeptide design strategy in a system that is highly relevant and tractable, and will likely provide leads for future drug development. In Aim 3 we develop methods to synthesize, analyze, and screen beta-peptide combinatorial libraries, and use them to optimize the affinities (and minimize the size) of beta-peptides identified in Aims 1 and 2. This aim also includes an experiment to identify cell-permeable beta53-1 library members, information that will guide design of beta-peptide ligands for additional validated targets. Taken together, the experiments in this application will provide fundamental information on ligand design and help achieve 1 of the most central and critical (yet unmet) goals of chemical biology research, the rapid identification of high affinity ligands for the vast array of potential non-enzymatic protein targets.

描述（由申请人提供）：该申请建立在我们实验室最近的研究结果的基础上，详细介绍了设计β肽的一般策略，这些β肽在水中具有高度的14-螺旋结构，并与蛋白质表面（如hDM2的p53AD相互作用结构域）具有高亲和力。在Aim 1中，我们探索了有助于14-螺旋在水中稳定性的结构特征，以及14-螺旋β肽β - 53-1识别蛋白质表面的能力。我们将完成一个广泛的“主-客”分析，将所有蛋白质生成和选择的非蛋白质生成侧链分类为14-螺旋稳定、不稳定或中性，生成一个位置依赖的数据库，14-螺旋在水中的倾向；确定beta53-1的核磁共振溶液结构，以支持主-客数据并指导未来的设计工作；并探讨引入环ACHC残基是否可以提高beta53-1的稳定性或亲和力。在目标2中，我们以目标1的结果为基础，为三种威胁人类健康和国家安全的病毒（HIV、人类呼吸道合胞病毒（HRSV）和导致严重急性呼吸道综合征（SARS-CoV）的冠状病毒）的包膜糖蛋白设计β肽配体。Aim 2中的实验将在一个高度相关和易于处理的系统中验证我们的β肽设计策略，并可能为未来的药物开发提供线索。在目标3中，我们开发了合成、分析和筛选β肽组合文库的方法，并使用它们来优化目标1和目标2中鉴定的β肽的亲和性（并最小化大小）。这一目标还包括鉴定细胞渗透性β - 53-1文库成员的实验，这些信息将指导β肽配体的设计，以用于其他经过验证的靶标。综上所述，本应用中的实验将提供配体设计的基本信息，并有助于实现化学生物学研究中最核心和最关键（尚未实现）的目标之一，即快速识别大量潜在的非酶蛋白靶标的高亲和力配体。